Jul 03,2023

Smart Insulin Pens Market to Worth USD 264.9 Million by 2030

The smart insulin pens market is projected to reach USD 264.9 million by 2030, according to the publisher. Major players include Emperra GmbH, Novo Nordisk, Medtronic, Eli Lilly, and Sanofi. The home care settings segment is expected to dominate the market, with North America being a significant contributor.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jul 04,2023 TOP STORY

Dexcom G7 Receives Health Canada Approval

Health Canada has approved the Dexcom G7 Continuous Glucose Monitoring System for people with diabetes in Canada. The next-generation CGM system offers unmatched accuracy, simplicity, and improved diabetes management. Dexcom G7 aims to make glucose monitoring easier and has been shown to reduce hospitalizations and emergency room visits due to hypoglycemia. The system will be available in Canada by the end of 2023.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 05,2023

Insulet to Announce Second Quarter 2023 Financial Results on August 8, 2023

Insulet Corporation, the global leader in tubeless insulin pump technology, will release its second-quarter 2023 financial results on August 8, 2023, followed by a conference call at 4:30 p.m. Eastern Time.

View Analyst & Ambassador Comments
Go to original news
Jun 26,2023

New Research Demonstrates 2.3 Point Reduction in HbA1c for Dario Digital Health Users with Baseline HbA1c Greater Than 9 points

A retrospective cohort study presented at the American Diabetes Association 83rd Scientific Sessions showed that Dario digital health users achieved a 2.3 point reduction in HbA1c for baseline HbA1c greater than 9 points, compared to a 1.8 point reduction with standard care. The new research presented at the Scientific Sessions used HIPAA-complaint deidentified patient data linking claims, electronic medical record and laboratory results data to construct a study cohort of 568 Dario users and 1,699 matched non-users. The analysis segmented study participants into four bands according to baseline HbA1c and analyzed HbA1c lab results for Dario users against a closely matched population of non-users over a period of six months. The study highlights the potential of digital health solutions in improving outcomes for serious diabetes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Rimidi Joins Henry Schein Medical SolutionsHub

Rimidi announced today a new distribution agreement with Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. As a result of this new agreement, Rimidi is part of the Henry Schein Medical SolutionsHub, and Henry Schein will offer its clinic, medical group, and health system customers access to Rimidi’s cloud-based software platform, further enhancing efforts to support efficient models of care for chronic disease management. Current clinical use cases of the Rimidi platform include chronic, cardiometabolic conditions, epidemic management, and perioperative care.

COLLABORATION PARTNERSHIP

#institution

#rpm

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Boston hospital remotely monitors new moms through Epic app

Boston Medical Center is remotely monitoring new mothers for conditions like postpartum hypertension to keep the women well and out of the hospital. The academic medical center employs the Rimidi care management platform, part of Epic's app store. The hospital is expanding the program to monitor for gestational hypertension, via cellular blood pressure cuffs, and gestational diabetes, through cellular glucometers.

COLLABORATION PARTNERSHIP

#institution

#rpm

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Rimidi and Boston Medical Center Release Metrics from Ongoing Remote Monitoring Program for Postpartum Hypertension

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, and Boston Medical Center, a private, not-for-profit academic medical center in New England, today released metrics from an ongoing remote patient monitoring program for new moms at high-risk of postpartum hypertension. Boston Medical Center leveraged the Rimidi platform to bring remotely-generated patient data from cellular-connected blood pressure cuffs into their clinical workflow. As part of Epic’s app orchard, Rimidi launches directly within the BMC team’s Epic experience. Resulting from the initial success of Boston Medical Center’s postpartum hypertension program, the center is now expanding the program to include monitoring for gestational hypertension, using cellular blood pressure cuffs and gestational diabetes, using cellular glucometers and FreeStyle Libre Continuous Glucose Monitors.

CLINICAL STUDY

#rpm

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Rimidi Showcases Addition of Glycemic Risk Index to Diabetes Management Platform, Announces Enhanced Integration with Dexcom

Rimidi announced today enhancements to its diabetes management platform, including the addition of Glycemic Risk Index (GRI) as an emerging tool for patient and population outcomes management. The inclusion of CGM data and GRI into Rimidi’s platform and clinical workflows is made possible via an enhanced integration with Dexcom, a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes. Through the collaboration, glycemic control metrics will enable more proactive and personalized management of diabetes across populations to drive better care decisions. This metric can be used to assess how well a patient is doing over time, manage a population and predict outcomes in intervention studies. The composite score is also thought to better correlate with the risk of complications and help identify areas for therapy adjustment.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 27,2023

Nemaura Medical Scales-Up Pilot Expansion of proBEAT™; 56 Corporations in the U.S. Signed Up for Pilots in June 2023

Nemaura Medical, a medical technology company, announces the pilot expansion of its proBEAT™ wearable sensor and AI-based feedback platform in the US. Over 50 corporations have signed up for pilots in June 2023. The program aims to provide cost-effective diabetes care solutions and personalized weight reduction programs. The company's innovation marks significant progress towards revenue generation and brings more innovative diabetes care solutions to the market.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 29,2023

Digital Diabetes Management Market by Product, Device Type, End User

The global digital diabetes management market is projected to reach USD 31.3 billion by 2028, growing at a CAGR of 13.3%, by the publisher of the report. Key drivers include the rising prevalence of diabetes and the adoption of cloud-based solutions and connected devices. The market is led by smart glucose meters and wearable devices, with North America as the largest market. Key players include Medtronic, Dexcom, Abbott Laboratories, Ypsomed Holding AG, and Roche.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES